文献速递肝肾功能剂量调整药物不良反应与药物警戒特殊人群用药

Upacicalcet在血液透析继发性甲状旁腺功能亢进患者中的首次人体I/II期研究:药代与药效学特征

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties.
PubMed 文献 · Clin Pharmacokinet · 2022-06-28

该研究为多中心、随机、安慰剂对照、双盲、剂量递增的I/II期试验,在血液透析继发性甲状旁腺功能亢进患者中评估Upacicalcet单次和多次静脉给药。结果显示血药浓度呈剂量依赖性升高并维持至下次透析,单次透析约清除80%,重复给药无蓄积,血清iPTH和校正钙呈下降趋势,未发现该药特有的安全性或耐受性问题。

要点

  • Upacicalcet血药浓度随剂量增加而升高,并可维持至下一次透析。
  • 单次透析约清除80%的药物,重复给药未见血浆浓度升高。
  • 血清iPTH和校正钙水平随血药浓度呈下降趋势。

核心结论

  • Upacicalcet对血液透析继发性甲状旁腺功能亢进患者呈剂量依赖性作用,且可持续至下次透析。
  • 未发现Upacicalcet特有的安全性或耐受性问题。

研究设计与样本

  • 多中心、随机、安慰剂对照、双盲、剂量递增的I/II期研究,含单次给药和多次给药两部分。
  • 单次给药研究设0.025至0.8 mg共7个剂量组,每步6例按2:1随机接受Upacicalcet或安慰剂。
  • 多次给药研究为期3周,设0.05至0.2 mg共3个剂量组,每步12例按3:1随机接受Upacicalcet或安慰剂。

主要发现

  • Upacicalcet血浆浓度呈剂量依赖性升高,并维持至下一次透析。
  • 单次透析约清除80%的Upacicalcet,重复给药后血浆浓度未见升高。
  • 血清完整甲状旁腺激素和校正钙水平随Upacicalcet血浆浓度呈下降趋势。
  • 单次给药研究中,接受Upacicalcet ≥0.4 mg的组别出现轻度、非严重上消化道症状。
  • 多次给药研究中,0.1 mg和0.2 mg组每位患者均出现腹部不适。

临床怎么用

  • Upacicalcet可考虑用于血液透析继发性甲状旁腺功能亢进患者,其作用呈剂量依赖性并可持续至下次透析。
  • 给药后需关注上消化道症状,尤其是较高剂量时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Upacicalcet is a new renally excreted and injectable calcimimetic agent. We evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of single and multiple intravenous administration of upacicalcet in patients with secondary hyperparathyroidism undergoing hemodialysis. METHODS: This study was a multicenter, randomized, placebo-controlled, double-blinded, dose-escalation study consisting of a single-dose study and a multiple-dose study. The single-dose study consisted of seven dose steps from 0.025 to 0.8 mg. For each step, six patients were randomly assigned 2:1 to receive upacicalcet or a placebo. The multiple-dose study occurred over 3 weeks in three-dose steps from 0.05 to 0.2 mg. For each step, 12 patients were randomly assigned 3:1 to receive upacicalcet or a placebo. RESULTS: The plasma concentration of upacicalcet increased in a dose-dependent manner and was maintained for the next dialysis. Upacicalcet was approximately 80% removed by a single dialysis and did not increase in the plasma concentration with repeated administration. Serum intact parathyroid hormone and corrected calcium (Ca2+) levels tended to decrease in response to the plasma concentration of upacicalcet. In the single-dose study, upper gastrointestinal symptoms were observed as a non-serious and mild adverse drug reaction in the groups receiving upacicalcet ≥ 0.4 mg. In the multiple-dose study, abdominal discomfort occurred in each patient in the 0.1 mg and 0.2 mg groups. CONCLUSIONS: Upacicalcet for patients with secondary hyperparathyroidism undergoing hemodialysis could be a calcimimetic agent that acts in a dose-dependent manner and persistently until the next dialysis session. No safety or tolerability issues specific to upacicalcet were found.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Kazama JJ, Koiwa F, Yokoyama K, et al. First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties. Clin Pharmacokinet. 2022. PMID: 35763247. doi:10.1007/s40262-022-01139-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。